A study conducted by Zhang et al. investigated the influence of nivolumab, an anti-PD-1 monoclonal antibody commonly utilized for melanoma treatment, on the presence of C2 levels, survival times, and TLS formation. The gene discussed is PDCD1; the disease is melanoma.